Abstract
Poly(ADP-ribose) polymerase (PARP) proteins are used by cells in several DNA repair processes. PARP inhibition can result in preferential death of cancer cells when another mechanism for repairing DNA is defective. Two PARP inhibitors, olaparib and rucaparib, have been approved by the US Food and Drug Administration (FDA) for the treatment of recurrent, BRCA-associated ovarian cancer. More recently, these two and a third PARP inhibitor, niraparib, were approved by the FDA as maintenance therapy following platinum-based chemotherapy for recurrent ovarian cancer. This has caused a paradigm shift in disease management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment. The oral formulation is attractive to patients, but adverse effects such as nausea and fatigue can impact quality of life. As clinicians become comfortable selecting PARP inhibitors and managing associated toxicities, future steps will be to investigate how to safely administer them in combination with other therapies.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Anemia / chemically induced
-
Anemia / prevention & control
-
Creatinine / blood
-
Drug Administration Schedule
-
Drug Interactions
-
Exanthema / chemically induced
-
Exanthema / prevention & control
-
Fatigue / chemically induced
-
Fatigue / prevention & control
-
Female
-
Genes, BRCA1
-
Genes, BRCA2
-
Heart Rate / drug effects
-
Humans
-
Hypertension / chemically induced
-
Hypertension / prevention & control
-
Indazoles / therapeutic use
-
Leukopenia / chemically induced
-
Leukopenia / prevention & control
-
Mutation
-
Myelodysplastic Syndromes / chemically induced
-
Nasopharyngitis / chemically induced
-
Nasopharyngitis / prevention & control
-
Nausea / chemically induced
-
Nausea / prevention & control
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / genetics
-
Piperidines / therapeutic use
-
Pneumonia / chemically induced
-
Poly(ADP-ribose) Polymerase Inhibitors / economics
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
-
Thrombocytopenia / chemically induced
-
Thrombocytopenia / prevention & control
-
Transaminases / blood
-
Vomiting / chemically induced
-
Vomiting / prevention & control
Substances
-
Indazoles
-
Piperidines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Creatinine
-
Transaminases
-
niraparib